Merck jumped 5 percent on news that regulators will do a quick review of one of its cancer drugs.
Associated Press, St. Louis Post-Dispatch: Business
Wed, 01/11/2017 - 7:43am
Merck jumped 5 percent on news that regulators will do a quick review of one of its cancer drugs.